Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010

Immunology Letters

Volumn 134, Issue 2, 2011, Pages 145-149

  Faure, Gilbert C ^a   Amsellem, Sophie ^b   Arnoulet, Christine ^c   Bardet, Valérie ^d   Campos, Lydia ^e   De Carvalho Bittencourt, Marcelo ^a   de Labarthe, Adrienne ^f   Eischen, Alice ^g   Feuillard, Jean ^h   Fossat, Chantal ⁱ   Ottou, Francine Garnache ^j   Guérin, Estelle ^h   Guy, Julien ^k   Jouault, Hélène ^l   Kuhlein, Emilienne ^m   Lacombe, Francis ⁿ   Lainey, Elodie ^o   Maynadié, Marc ^k   Noguera, Maria Elena ^f   Roussel, Mikael ^p   Solly, Françoise ^e   Ballon, Orianne Wagner ^l   Béné, Marie C ^a   more..

^a CHU NANCY BRABOIS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d Institut Cochin   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ TIMONE HOSPITAL   (France)

^j ETABLISSEMENT FRANÇAIS DU SANG   (France)

^k DIJON UNIVERSITY HOSPITAL   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m CHU PURPAN   (France)

ⁿ HAUT LÉVÊQUE HOSPITAL   (France)

^o HÔPITAL ROBERT DEBRÉ   (France)

^p PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Acute lymphoblastic leukemia; B lineage; Immunophenotyping

Indexed keywords

CD200 ANTIGEN; CD299 ANTIGEN; CD305 ANTIGEN; CD361 ANTIGEN; DIFFERENTIATION ANTIGEN; HUMAN LEUKOCYTE DIFFERENTIATION ANTIGEN; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBODY LABELING; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; CELL CLONE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INFANT; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 78650296546     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.10.008     Document Type: Article

References (33)

1. http://www.assim.refer.org/.
2. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
3. Leucocyte typing: human leucocyte differentiation antigens detected by monoclonal antibodies 1984, Springer-Verlag, Berlin. A.R. Bernard, L. Boumsell, J. Dausset, C. Milstein, S.F. Schlossman (Eds.).
4. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995, 9:1783-1786.
5. http://www.leukemia-net.org/content/diagnostics/diagnostics/documents/.
6. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
7. Kozlow E.J., Wilson G.L., Fox C.H., Kehrl J.H. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 1993, 81:454-461.
8. Prazma C.M., Yazawa N., Fujimoto Y., Fujimoto M., Tedder T.F. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J Immunol 2007, 179:4550-4562.
9. Tamura H., Ogata K., Dong H., Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 2003, 78:321-328.
10. Kennedy J., Vicari A.P., Saylor V., Zurawski S.M., Copeland N.G., Gilbert D.J., et al. A molecular analysis of NKT cells: identification of a class-I restricted T cell-associated molecule (CRTAM). J Leukoc Biol 2000, 67:725-734.
11. Davis R.S. Fc receptor-like molecules. Annu Rev Immunol 2007, 25:525-560.
12. Merlo A., Tenca C., Fais F., Battini L., Ciccone E., Grossi C.E., et al. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 2005, 12:705-712.
13. Meyaard L., Adema G.J., Chang C., Woollatt E., Sutherland G.R., Lanier L.L., et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997, 7:283-290.
14. Del Valle J.M., Engel P., Martín M. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem 2003, 278:17430-17437.
15. Wright G.J., Jones M., Puklavec M.J., Brown M.H., Barclay A.N. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001, 102:173-179.
16. Brunetti L., Di Noto R., Abate G., Gorrese M., Gravetti A., Raia M., et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009, 145:665-667.
17. Palumbo G.A., Parrinello N., Fargione G., Cardillo K., Chiarenza A., Berretta S., et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009, 33:1212-1216.
18. Aalto Y., El-Rifa W., Vilpo L., Ollila J., Nagy B., Vihinen M., et al. Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 2001, 15:1721-1728.
19. Broxmeyer H.E. Chemokines in hematopoiesis. Curr Opin Hematol 2008, 15:49-58.
20. Maecker H., Varfolomeev E., Kischkel F., Lawrence D., LeBlanc H., Lee W., et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123:931-944.
21. Schneider P., Schwenzer R., Haas E., Mühlenbeck F., Schubert G., Scheurich P., et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999, 29:1785-1792.
22. Del Rio M.L., Lucas C.L., Buhler L., Rayat G., Rodriguez-Barbosa J.I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2010, 87:223-235.
23. Watts T.H., Gommerman J.L. The LIGHT and DARC sides of herpesvirus entry mediator. Proc Natl Acad Sci U S A 2005, 102:13365-13366.
24. Nocentini G., Ronchetti S., Cuzzocrea S., Riccardi C. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 2007, 37:1165-1169.
25. Day E.S., Cachero T.G., Qian F., Sun Y., Wen D., Pelletier M., et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005, 44:1919-1931.
26. Biomedical platforms-realigning the normal and the pathological in late-twentieth-century medicine 2003, MIT Press, Cambridge. P. Keating, A. Cambrosio (Eds.).
27. Lenormand B., Béné M.C., Lesesve J.F., Bastard C., Tilly H., Lefranc M.P., et al. PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies. Leuk Lymphoma 1998, 28:329-342.
28. Maury S., Huguet F., Leguay T., Lacombe F., Maynadié M., Girard S., et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 2010, 20:324-328.
29. Davis B.H., Holden J.T., Bene M.C., Borowitz M.J., Braylan R.C., Cornfield D., et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom 2007, 72S1:S5-S13.
30. Béné M.C., Kaeda J.S. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 2009, 94:1135-1150.
31. Lacombe F., Arnoulet C., Maynadié M., Lippert E., Luquet I., Pigneux A., et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009, 23:350-357.
32. Chevallier P., Robillard N., Houille G., Ayari S., Guillaume T., Delaunay J., et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia 2009, 23:806-807.
33. Arnoulet C., Béné M.C., Durrieu F., Feuillard J., Fossat C., Husson B., et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom 2010, 78:4-10.